K145

K145 is a selective, substrate-competitive, and orally active small molecule inhibitor of sphingosine kinase 2 (SphK2) with an IC50 of 4.3 µM and a Ki of 6.4 µM. Developed by researchers at Virginia Commonwealth University and Shandong University, K145 selectively targets SphK2 over SphK1, ceramide kinase, and other protein kinases. In preclinical studies, K145 has been shown to accumulate in cells, suppress sphingosine-1-phosphate (S1P) levels, induce apoptosis, and inhibit downstream ERK and Akt signaling pathways. It has demonstrated antitumor activity in leukemia and breast cancer models, and has also been investigated for its potential in metabolic diseases such as non-alcoholic fatty liver disease (NAFLD) and hyperglycemia. K145 is widely used as a chemical biology tool and research reagent.

Other names

3-(2-amino-ethyl)-5-[3-(4-butoxyl-phenyl)-propylidene]-thiazolidine-2,4-dione3-(2-aminoethyl)-5-(3-(4-butoxyphenyl)propylidene)-1,3-thiazolidine-2,4-dione3-(2-aminoethyl)-5-(3-(4-butoxyphenyl)propylidene)thiazolidine-2,4-dioneK-145K145K 145